Darwin deal

Rhone-Poulenc Rorer took a $5 million equity position in the Bothell, Wash., company. The initial focus of the four-year agreement is a gene therapy for cancer that will use Darwin's herpes thymidine kinase genes, in combination with RPR's vectors and gene delivery technology. ...